Analysts Offer Predictions for TNDM FY2025 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Leerink Partnrs issued their FY2025 earnings estimates for Tandem Diabetes Care in a research report issued to clients and investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky expects that the medical device company will earn ($1.30) per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2027 earnings at ($0.01) EPS.

TNDM has been the topic of several other research reports. Robert W. Baird dropped their price target on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a “neutral” rating on the stock in a research note on Thursday, May 1st. Truist Financial began coverage on shares of Tandem Diabetes Care in a research note on Monday, June 16th. They issued a “hold” rating and a $24.00 price target on the stock. Stifel Nicolaus dropped their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Canaccord Genuity Group raised their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Finally, Mizuho began coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a “neutral” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $32.71.

Tandem Diabetes Care Price Performance

TNDM opened at $15.75 on Wednesday. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -5.67 and a beta of 1.48. Tandem Diabetes Care has a fifty-two week low of $14.87 and a fifty-two week high of $48.24. The company’s 50-day moving average price is $19.93 and its 200 day moving average price is $24.04. The company has a quick ratio of 1.81, a current ratio of 2.30 and a debt-to-equity ratio of 1.99.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The business had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. Tandem Diabetes Care’s revenue was up 22.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.65) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TNDM. Sessa Capital IM L.P. bought a new position in shares of Tandem Diabetes Care in the first quarter valued at approximately $85,574,000. Hood River Capital Management LLC bought a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $46,035,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Tandem Diabetes Care by 189.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company’s stock valued at $59,830,000 after acquiring an additional 1,086,337 shares in the last quarter. Brown Advisory Inc. bought a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $32,889,000. Finally, GW&K Investment Management LLC boosted its holdings in shares of Tandem Diabetes Care by 34.9% in the first quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company’s stock valued at $54,874,000 after acquiring an additional 740,499 shares in the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.